Clinical Study on Lowering Blood Lipid Level by Lifestyle Control Combined with Nattokinase (NK) - Red Yeast Rice (RYR) Capsules

Abstract

Abstract: Objective To study the efficacy and safety of lifestyle control combined with Nattokinase Red yeast rice(NK-RYR) capsules in reducing blood lipids. Methods Hyperlipidemia volunteers were recruited according to inclusion and exclusion criteria, and randomly divided into NK-RYR capsules group (lifestyle control + NK-RYR capsules) with 20 cases and lifestyle control group (lifestyle control alone) with 10 cases according to the ratio of 2:1. Lifestyle control was carried out in both groups during the experiment. The NK-RYR capsules group received Chongjian NK-RYR capsules (1.35g bid) at the same time, for a total of 90 days. All subjects were interviewed on 0 d, 30 d, 60 d and 90 d after enrollment, and the four items of blood lipids, liver and kidney function and adverse events at each site were recorded on 0d and 90d. Four items of blood lipids, changes of liver and kidney function and adverse events before and after the two groups were compared. Results Low density lipoprotein cholesterol (LDL-C) was significantly decreased in the NK-RYR capsules group before and after the test (P<0.05). total cholesterol (TC) decreased significantly (P<0.05); There was no significant difference in LDL-C and TC levels in lifestyle control group (P>0.05). There was no significant difference in High density lipoprotein cholesterol (HDL-C) between the two groups before and after each test (P>0.05). There was no significant difference in triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine before and after the trial between the two groups (P>0.05), and no adverse events occurred during the trial between the two groups. Conclusion Compared with lifestyle control alone, the combination of lifestyle control and NK-RYR capsules can reduce LDL-C and TC levels in hyperlipidemia patients.

Key words: lifestyle control, NK-RYR Capsules, LDL-C, TC

CLC Number:

R741

YU Feng-chun, ZHOU Yang, ZHANG Xin-yu, FAN Cheng-zhe, LI Hui-jun, SONG Zhe, CHEN Zhi-gang, BI Qi. Clinical Study on Lowering Blood Lipid Level by Lifestyle Control Combined with Nattokinase (NK) - Red Yeast Rice (RYR) Capsules[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(4): 15-19.

References

[1] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.血脂异常基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2019,18(5):417-421.
[2] 中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等.中国心血管病一级预防指南[J].中华心血管病杂志,2020,48(12):1000-1038.
[3] 北京神经内科学会,纳豆激酶在血管病危险人群应用专家建议(2020版)[J].中国老年保健医学,2022,20(1):3-8.
[4] CHEN H, CHEN J, ZHANG F, et al.Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants[J]. Front Cardiovasc Med,2022,9:964977.
[5] 中国老年学和老年医学学会心脑血管病专业委员会,血脂康(胶囊)临床应用中国专家共识组.血脂康(胶囊)临床应用中国专家共识(2017修订版)[J].中华内科杂志,2018,57(2):97-100.
[6] 中国心脏联盟,中国康复医学会心脏预防与康复专业委员会,脂必泰胶囊临床应用中国专家共识组.脂必泰胶囊临床应用中国专家共识[J].中华内科杂志,2017,56(8):628-632.
[7] CICERO A F G, COLLETTI A, BAJRAKTARI G, et al. Lipid-lowering nutraceuticals in clinical practice : position paper from an International Lipid expert Panel[J]. NUTR REV,75(9):731-767.
[8] MACIEJ BANACH, ALBERICO L, CATAPANO, ARRIGO F.G. CICER, et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel[J]. PHARMACOL RES,183:106370.
[9] 国家心血管病专家委员会心血管代谢医学专业委员会.基层血脂管理适宜技术中国专家建议(2022 版)[J].中国循环杂志,2022.37(12):1181-1185.
[10] 《动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识》编写组.动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识[J].临床药物治疗杂志,2023,21(2):7-16.
[11] BROWN C J, CHANG L S, HOSOMURA N, et al.Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk[J]. JAMA Netw Open,2023,6(2):e231047.
[12] 国家食品药品监督管理局.关于以红曲等为原料保健食品产品申报与审评有关事项的通知[EB/OL]. 2010-1-5[2010-1-11]http://www.gov.cn/gzdt/2010-01/11/content_1507641.htm.
[13] NIEMELä O, BLOIGU A, BLOIGU R.et al.Impact of Physical Activity on the Characteristics and Metabolic Consequences of Alcohol Consumption: A Cross-Sectional Population-Based Study[J]. Int J Environ Res Public Health,2022,19(22):15048.
[14] XIONG X, WANG P, LI X, et al.The Effects of Red Yeast rice Dietary Supplement on Blood Pressure, Lipid Profile, and C-Reactive Protein in Hypertension: A Systematic Review[J]. Crit. Rev. Food Sci. Nutr,2017, 57(9):1831-1851.
[15] SUNGTHONG B, YOOTHAEKOOL C, PROMPHAMORN, et al. Efficacy of Red Yeast rice Extract on Myocardial Infarction Patients with Borderline Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials[J]. Sci. Rep,2020,10(1):2769.
[16] YUAN R, YUAN Y, WANG L, et al.Red Yeast Rice Preparations Reduce Mortality, Major Cardiovascular Adverse Events, and Risk Factors for Metabolic Syndrome: A Systematic Review and Meta-analysis[J]. Front Pharmacol,13:744928.
[17] RAHMANI P, MELEKOGLU E, TAVAKOLI S.et al.Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials[J]. Expert review of clinical pharmacology,2023,16(1):73-81.
[18] 中国血脂管理指南修订联合专家委员会.中国血脂管理指南(2023年)[J].中国循环杂志,2023,38(3):237-269.